- TheStreet.com•16 days ago
This biopharma company's Relistor drug should send revenues sharply higher this year.
- MarketWatch•28 days ago
Progenics Pharmaceuticals Inc. shares rallied in the extended session Thursday after the cancer drug company said its clinical trial of a prostate cancer imaging agent will continue. Progenics shares surged ...
- GlobeNewswire•28 days agoProgenics Pharmaceuticals Announces Independent Committee’s Positive Recommendation for Continuation of Phase 3 Clinical Trial of SPECT/CT Imaging Agent 1404
NEW YORK, Dec. 22, 2016-- Progenics Pharmaceuticals, Inc., an oncology company developing innovative medicines and other technologies for targeting and treating cancer, today announced that its independent ...
PGNX : Summary for Progenics Pharmaceuticals Inc. - Yahoo Finance
Progenics Pharmaceuticals, Inc. (PGNX)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||8.90 x 900|
|Ask||8.91 x 400|
|Day's Range||8.85 - 9.16|
|52 Week Range||3.61 - 9.78|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||57.55|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|